A medical condition in which age-related testosterone decline produces a constellation of physical and psychological symptoms in men. English distinguishes the clinical term Late-Onset Hypogonadism (LOH) from the popular male menopause (or andropause); the medical community generally prefers LOH in clinical and diagnostic settings, while popular usage prefers male menopause by analogy with the female condition.

Overview

Male menopause (Japanese: 男性更年期, dansei-kōnenki; clinical English: Late-Onset Hypogonadism, LOH syndrome; popular English: male menopause, andropause, age-related testosterone deficiency) refers to the medical condition in which age-related testosterone decline produces clinically significant symptoms across the physical, sexual, and psychological domains. The condition was conceptualised as a male analogue of female menopause from the late twentieth century onward, and the formal clinical framework around LOH was established through international andrological-society guidelines in the early 2000s.

Its epidemiology shows wide individual variation. Not every man with age-related testosterone decline develops symptomatic LOH, and the threshold for clinical significance combines biochemical criteria (testosterone level) with symptomatic ones. The reported prevalence of symptomatic LOH in Japanese men is roughly 20 percent in the forties, 40 percent in the fifties, and 60 percent in the sixties, though these figures vary with survey methodology and with the symptom threshold used.

Distinction in vocabulary

English distinguishes three principal terms, overlapping but with distinct registers:

• Late-Onset Hypogonadism (LOH): the clinical and medical term, preferred in academic and clinical writing. It frames the condition as hypogonadism, that is, deficient gonadal function.
• Male menopause: the everyday term, formed by direct analogy with female menopause. The analogy is controversial in the medical community. Critics argue that it mis-frames the condition: female menopause involves a relatively rapid hormonal transition concentrated around a defined age range, while LOH involves a gradual testosterone decline spread over decades.
• Andropause: an alternative coinage combining andro- (male) with -pause (cessation). It has had partial uptake but is less established than either male menopause or LOH.

The Japanese dansei-kōnenki (男性更年期) is a direct translation of “male menopause”, with kōnenki mirroring the Japanese vocabulary for the female condition. The clinical term LOH-shōkōgun (LOH症候群) parallels the English clinical LOH. Japanese popular usage relies on dansei-kōnenki and shares the same controversial analogy that English male menopause carries.

The distinction matters for how the condition is framed. LOH operates with substantial medical acceptance as a defined clinical entity. Male menopause and dansei-kōnenki carry broader cultural resonance but remain contested, because the implied equivalence with female menopause is questioned in the medical literature.

Pathophysiology

Testosterone is produced primarily by the Leydig cells of the testes. Levels peak in the twenties and thirties and then decline gradually from the forties onward at roughly 1 to 2 percent per year. By the eighties, most men have testosterone at 50 to 70 percent of their young-adult peak.

The rate of decline varies substantially between individuals, and men of the same age can show several-fold differences in serum testosterone. Lifestyle factors, including sleep quality, exercise, nutrition, and stress, modulate the rate; chronic stress, obesity, and sleep deprivation are particularly well recognised as accelerants.

The mechanism has both primary and secondary components. Leydig-cell function declines with age, reducing testicular output. The hypothalamic-pituitary axis also changes, with altered LH (luteinising hormone) pulse frequency and amplitude affecting downstream testicular stimulation. This combination of primary and secondary contributions distinguishes LOH from purely primary or purely secondary hypogonadism.

Symptoms

LOH symptoms are diverse and largely non-specific, which makes diagnostic recognition difficult. The vague “something feels off” presentation is one of the principal diagnostic challenges of the condition.

Sexual-function symptoms

• Reduced libido
• Erectile dysfunction
• Loss of morning erections (asa-dachi)
• Reduced ejaculate volume
• Diminished orgasm intensity

Psychological and neural symptoms

• Reduced motivation and concentration
• Increased fatigue
• Depressed mood
• Insomnia
• Reduced memory

Physical symptoms

• Muscle-strength and muscle-mass loss
• Body-fat increase (particularly visceral adiposity)
• Bone-density decline
• Sweating and hot-flush episodes (analogous to female menopausal hot flashes)
• Body-hair changes

The configuration of symptoms varies substantially between patients. Some present mainly with sexual-function complaints, others with low mood and fatigue, others with changes in body composition.

Diagnosis

Diagnosis requires both a symptomatic presentation and biochemical confirmation. The standard self-administered symptom scale is the AMS (Aging Males’ Symptoms) Scale, used internationally as a screening instrument.

Biochemical testing uses an early-morning serum testosterone measurement, and several international guidelines treat a total testosterone below 8.0 nmol/L (or a substantial reduction in free testosterone) as the threshold at which treatment should be considered. The correlation between symptoms and biochemistry is imperfect: substantial individual variation in symptom presentation occurs at any given testosterone level, and the diagnostic judgement requires integrating both dimensions.

Differential diagnosis includes hypothyroidism, depression, sleep apnoea, and prostate-related conditions, all of which can produce overlapping symptom profiles. Comprehensive evaluation is standard practice.

Distinction from female menopause

The popular male menopause and dansei-kōnenki framings produce a structural comparison with female menopause that is illuminating in some respects and misleading in others.

In shared features, both conditions involve age-related hormonal change with consequent symptomatic effects, both produce symptoms across the physical, sexual, and psychological domains, both have established hormone-replacement-therapy options, and both involve substantial individual variation in presentation.

In distinct features, female menopause involves a rapid hormonal transition concentrated in the five-to-ten-year window of perimenopause, with cessation of ovarian function as the defining event. LOH involves a gradual decline of testosterone over decades, with no defined cessation. The age range of symptomatic onset is much more variable in LOH than the relatively compressed onset of female menopause. The defining biochemical criterion (cessation of ovarian function on the one hand, sub-threshold testosterone on the other) is structurally different.

The two conditions therefore share generic features but differ in temporal structure and defining mechanism. Medical concerns about the male menopause terminology turn on this distinction: the analogy implies a defined transition that LOH typically lacks.

Testosterone Replacement Therapy (TRT)

Testosterone Replacement Therapy (TRT) is the principal medical treatment for symptomatic LOH. The therapy administers exogenous testosterone in order to restore the deficient endogenous level, with the aim of improving symptoms.

Formulations

In Japan, intramuscular testosterone enanthate injection (250 mg every two to four weeks) is the principal insurance-approved formulation. Western markets have substantially broader options, including:

• Transdermal gels (daily application)
• Transdermal patches
• Subcutaneous pellet implants (long-acting, three to six months)
• Buccal-mucosa adhesive tablets
• Nasal-gel formulations
• Long-acting intramuscular testosterone undecanoate (every ten to fourteen weeks)

The greater variety available in Western markets allows substantial customisation of the route of administration to patient preference.

Benefits and risks

Appropriate TRT can improve libido, erectile function, energy, muscle mass, bone density, and mood, as shown in multiple clinical trials. The effects are typically dose-dependent and time-dependent, and symptomatic improvement frequently lags behind biochemical normalisation by weeks or months.

The adverse effects and risks include:

• Prostate effects. TRT may accelerate the growth of pre-existing prostate cancer; PSA (prostate-specific antigen) screening and monitoring are standard prerequisites.
• Polycythaemia. Testosterone stimulates red-blood-cell production and can elevate haematocrit, with attendant cardiovascular risk.
• Sleep apnoea. Testosterone may worsen pre-existing sleep apnoea.
• Suppression of spermatogenesis. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing endogenous testosterone production and spermatogenesis. This is a relevant consideration for fertility.
• Cardiovascular effects. The relationship between TRT and cardiovascular outcomes remains debated, with mixed findings across long-term observational and trial studies.

Standard practice includes regular monitoring of PSA, haematocrit, lipid profile, and clinical symptom response.

Lifestyle interventions

For mild LOH, lifestyle interventions are the first-line recommendation. Aerobic exercise and resistance training have a demonstrated effect of naturally raising testosterone levels, and high-intensity interval training (HIIT) shows particular efficacy in the research literature. Adequate sleep (seven to eight hours), moderate alcohol consumption, smoking cessation, and weight management all support testosterone maintenance.

These interventions function either as complements to TRT or as alternatives to it, depending on the severity of presentation and the patient’s individual context. In severe LOH, lifestyle measures alone may be insufficient; in mild LOH, they may be enough to maintain functional sexual and physical performance without exogenous hormone administration.

Position of the medical community

The position of the medical community on LOH as a clinical entity remains an active area of discussion. The American Endocrine Society and the International Society of Andrology have published clinical practice guidelines that establish the diagnostic criteria and treatment protocols. Some clinicians and researchers have raised continuing concerns about over-diagnosis and over-treatment, particularly in connection with direct-to-consumer TRT marketing in certain Western markets.

Contemporary clinical practice generally accepts symptomatic LOH as a treatable condition, while recommending careful diagnostic evaluation and ongoing monitoring of treated cases.

Related Terms

• Sex hormones
• Erectile dysfunction
• Libido
• Sexual desire and aging
• Erection (bokki)
• Partial loss of erection (nakaore)